



Who is eligible to apply?

This program is designed to help patients who:

- Have a diagnosis of intrahepatic cholangiocarcinoma or gastrointestinal tract cancer with liver metastases and who have been prescribed floxuridine.
- The patient must either have no insurance coverage for this medication or been denied insurance coverage for the medication.
- The patient must be a United States citizen or U.S. resident of six (6) months or greater.
- Meet the program's financial eligibility criteria.

NORD is Here for You

NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 300 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

NORD was founded by families struggling to obtain access to treatments and whose advocacy for change led to the passage of the Orphan Drug Act in 1983. NORD assists eligible patients (those with medical and financial needs) in affording the treatments and medical services their healthcare professionals have prescribed.



How do I get more information and apply? Contact NORD's Floxuridine Assistance Program

Monday-Thursday 8:30am – 7:00pm ET Friday 8:30 am – 6:00pm ET

C

203-516-0962



203-207-9896



floxuridine@rarediseases.org

=>>

US MAIL to: NORD Attention: Floxuridine Program 55 Kenosia Avenue Danbury, CT 06810

What is the application process?

- Patients may be referred to the program by their health care provider, their case managers, or they may self-refer.
- A NORD Patient Services Representative will guide the applicant through the application process, verify eligibility for inclusion in the Floxuridine Medication Assistance Program.
- Awards are based on meeting eligibility criteria, and are made on a first-come, first served basis.

Once a patient is accepted into the assistance program(s), what happens?

- NORD will notify the patient and his/her physician of enrollment in the program.
- It is necessary for the patient and/or the physician to notify NORD of medication administration appointments.
- When NORD receives confirmation of appointment date, we will arrange for shipment of your floxuridine medication directly to the prescribing physician.
- The patient and his/her physician are requested to notify NORD of subsequent floxuridine infusion appointments as soon as possible to prevent delay in medication shipment.

What happens if an applicant does not meet the criteria of the Electronic Income Verification?

The NORD Patient Services Representative will offer to e-mail, fax, or mail the brief program application to the patient. The applicant may then complete the application, and provide the appropriate financial documentation to verify financial need, and return them via fax, email, or USPS mail.

How does NORD demonstrate compliance with regulations required of charities?

- NORD independently designs its patient assistance programs based on the needs of specific patient communities.
- No pharmaceutical company or donor controls or influences our programs.
- Our patient assistance decisions are based on consistently applied financial eligibility criteria and diagnosis only.
- Patients have their choice of health care provider, treatment and treatment location, and can make changes at any time.
- Patients' privacy and well-being are priorities at NORD. We do not share or provide patient names or data with donors, nor do we disclose or identify donors to patients. Patients are able to make the choices that are best for them because NORD's assistance covers all FDA-approved products available for a diagnosis. Our programs also help with more than medication: patients can use their funds to pay for other physician prescribed services related to their diagnosis such as, laboratory and diagnostic testing, physical and occupational therapy, durable medical and adaptive equipment, and travel to medical appointments.

